Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | AL Amyloidosis | Case report

Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review

Authors: Ping Zhang, Xiuling Chen, Yurong Zou, Wei Wang, Yunlin Feng

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Backgrounds

Published literatures on repeat renal biopsy of AL amyloidosis have basically reached a consensus that amyloid material deposit does not disappear or diminish after satisfactory hematologic response, regardless of renal response. However, the need of a repeat renal biopsy in such situation is still controversial.

Case presentation

Here we reported a case of histologically confirmed λ Type renal AL amyloidosis who had been classified as Stage I and low risk at initial diagnosis. The patient received a total of six courses of CyBorD chemotherapy. She had achieved complete hematologic remission after two courses of chemotherapy but consistently had large amount of proteinuria over 10 g/day during follow up. A repeat renal biopsy was performed nine months after the first one and indicated mild to moderate increase of amyloid deposits as well as significant glomerulosclerosis and interstitial lesions, suggesting a lack of histological renal improvement despite her satisfactory hematologic response.

Conclusions

This case indicated renal involvement in AL amyloidosis could progress after successful hematologic treatment, and supported the value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhihong Liu XH. Nan Chen: Guideline for diagnosis and treatment of systemic AL amyloidosis. National Medical Journal of China. 2016;96(44):3540–8. Zhihong Liu XH. Nan Chen: Guideline for diagnosis and treatment of systemic AL amyloidosis. National Medical Journal of China. 2016;96(44):3540–8.
2.
go back to reference Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–7.CrossRef Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–7.CrossRef
3.
go back to reference Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460–6.CrossRef Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460–6.CrossRef
4.
go back to reference Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–9.CrossRef Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–9.CrossRef
5.
go back to reference Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid. 2020;27(1):17–24.CrossRef Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid. 2020;27(1):17–24.CrossRef
6.
go back to reference Okuyama H, Yamaya H, Fukusima T, Yokoyama H. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy. Clin Nephrol. 2013;79(3):233–6.CrossRef Okuyama H, Yamaya H, Fukusima T, Yokoyama H. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy. Clin Nephrol. 2013;79(3):233–6.CrossRef
7.
go back to reference Yamazaki O, Ubara Y, Suwabe T, Nakanishi S, Hoshino J, Sawa N, Hayami N, Yamanouchi M, Takemoto F, Kenmei T, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clin Exp Nephrol. 2009;13(5):522–5.CrossRef Yamazaki O, Ubara Y, Suwabe T, Nakanishi S, Hoshino J, Sawa N, Hayami N, Yamanouchi M, Takemoto F, Kenmei T, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clin Exp Nephrol. 2009;13(5):522–5.CrossRef
8.
go back to reference Nakayama M, Kashiwagi M, Katafuchi R, Hori K, Hayashi S, Fujimi S. Resolution of primary amyloidosis by melphalan and prednisolone: a case report. Clin Nephrol. 2005;63(3):215–20.CrossRef Nakayama M, Kashiwagi M, Katafuchi R, Hori K, Hayashi S, Fujimi S. Resolution of primary amyloidosis by melphalan and prednisolone: a case report. Clin Nephrol. 2005;63(3):215–20.CrossRef
9.
go back to reference Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982;142(8):1445–7.CrossRef Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982;142(8):1445–7.CrossRef
10.
go back to reference Safadi S, Saad A, Quint PS, Sethi S, Leung N, Kurtin P, Nasr SH. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis. Nephrol Dial Transplant. 2015;30(7):1151–5.CrossRef Safadi S, Saad A, Quint PS, Sethi S, Leung N, Kurtin P, Nasr SH. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis. Nephrol Dial Transplant. 2015;30(7):1151–5.CrossRef
11.
go back to reference Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79–89.CrossRef Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79–89.CrossRef
12.
go back to reference Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–34.CrossRef Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–34.CrossRef
13.
go back to reference Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59.CrossRef Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59.CrossRef
14.
go back to reference Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.CrossRef Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.CrossRef
15.
go back to reference Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, et al. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. Am J Hematol. 2020;95(11):1280–7.CrossRef Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, et al. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. Am J Hematol. 2020;95(11):1280–7.CrossRef
16.
go back to reference Rubinstein S, Cornell RF, Du L, Concepcion B, Goodman S, Harrell S, Horst S, Lenihan D, Slosky D, Fogo A, et al. Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid. 2017;24(3):205–11.CrossRef Rubinstein S, Cornell RF, Du L, Concepcion B, Goodman S, Harrell S, Horst S, Lenihan D, Slosky D, Fogo A, et al. Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid. 2017;24(3):205–11.CrossRef
17.
go back to reference Roth RM, Benson D, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Brodsky SV. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis. Arch Pathol Lab Med. 2013;137(9):1304–8.CrossRef Roth RM, Benson D, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Brodsky SV. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis. Arch Pathol Lab Med. 2013;137(9):1304–8.CrossRef
18.
go back to reference Zeier M, Perz J, Linke RP, Donini U, Waldherr R, Andrassy K, Ho AD, Goldschmidt H. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant. 2003;18(12):2644–7.CrossRef Zeier M, Perz J, Linke RP, Donini U, Waldherr R, Andrassy K, Ho AD, Goldschmidt H. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant. 2003;18(12):2644–7.CrossRef
19.
go back to reference Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, et al. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis. CEN Case Rep. 2020;9(1):6–10.CrossRef Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, et al. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis. CEN Case Rep. 2020;9(1):6–10.CrossRef
20.
go back to reference Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.CrossRef Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.CrossRef
21.
go back to reference Hetzel GR, Uhlig K, Mondry A, Helmchen U, Grabensee B. AL-amyloidosis of the kidney initially presenting as minimal change glomerulonephritis. Am J Kidney Dis. 2000;36(3):630–5.CrossRef Hetzel GR, Uhlig K, Mondry A, Helmchen U, Grabensee B. AL-amyloidosis of the kidney initially presenting as minimal change glomerulonephritis. Am J Kidney Dis. 2000;36(3):630–5.CrossRef
22.
go back to reference Fernando PB, Faria MS, Capucho R, Costa E, Guerra L, Faria V. Faria V: Non-Hodgkin lymphoma and glomerulonephritis. What kind of relation. Nephrol Dial Transplant. 1996;11(5):854–6.CrossRef Fernando PB, Faria MS, Capucho R, Costa E, Guerra L, Faria V. Faria V: Non-Hodgkin lymphoma and glomerulonephritis. What kind of relation. Nephrol Dial Transplant. 1996;11(5):854–6.CrossRef
23.
go back to reference Harper L, Adu D. Glomerulonephritis and non-Hodgkin lymphoma. Nephrol Dial Transplant. 1997;12(7):1520–5.CrossRef Harper L, Adu D. Glomerulonephritis and non-Hodgkin lymphoma. Nephrol Dial Transplant. 1997;12(7):1520–5.CrossRef
24.
go back to reference Fukunaga S, Hoshino Y, Ooba M, Kawanishi M, Yoshikane K, Egawa M, Ito T, Tanabe K. Investigation of the safety and usefulness of a renal biopsy for older elderly patients >/=75 years old. Nihon Ronen Igakkai Zasshi. 2021;58(3):453–8.CrossRef Fukunaga S, Hoshino Y, Ooba M, Kawanishi M, Yoshikane K, Egawa M, Ito T, Tanabe K. Investigation of the safety and usefulness of a renal biopsy for older elderly patients >/=75 years old. Nihon Ronen Igakkai Zasshi. 2021;58(3):453–8.CrossRef
25.
go back to reference Torigoe K, Muta K, Tsuji K, Yamashita A, Abe S, Ota Y, Mukae H, Nishino T. Safety of Renal Biopsy by Physicians with Short Nephrology Experience. Healthcare (Basel). 2021;9(4):474.CrossRef Torigoe K, Muta K, Tsuji K, Yamashita A, Abe S, Ota Y, Mukae H, Nishino T. Safety of Renal Biopsy by Physicians with Short Nephrology Experience. Healthcare (Basel). 2021;9(4):474.CrossRef
Metadata
Title
Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review
Authors
Ping Zhang
Xiuling Chen
Yurong Zou
Wei Wang
Yunlin Feng
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
AL Amyloidosis
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02752-4

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.